Gemini Therapeutics, Inc. (GMTX): Price and Financial Metrics
GMTX Price/Volume Stats
|Current price||$13.50||52-week high||$14.10|
|Prev. close||$1.35||52-week low||$1.16|
|Day high||$14.10||Avg. volume||189,291|
|50-day MA||$1.68||Dividend yield||N/A|
|200-day MA||$1.57||Market Cap||584.93M|
GMTX Stock Price Chart Interactive Chart >
Gemini Therapeutics, Inc. (GMTX) Company Bio
Gemini Therapeutics, Inc. operates as a precision medicine company. The Company focuses on dry macular degeneration which is a disease comprised of numerous genetic variants. Gemini Therapeutics serves customers worldwide.
GMTX Latest News Stream
|Loading, please wait...|
GMTX Latest Social Stream
View Full GMTX Social Stream
Latest GMTX News From Around the Web
Below are the latest news stories about GEMINI THERAPEUTICS INC that investors may wish to consider to help them evaluate GMTX as an investment opportunity.
While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists.
Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)
Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today the initiation of AURORA, a Phase 2 clinical study of bitopertin in adults with EPP. Bitopertin is an oral, selective inhibitor of glycine transporter 1 (GlyT1) designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX (
WAYLAND, Mass. & WATERTOWN, Mass., August 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX) ("Gemini") and Disc Medicine, Inc. ("Disc"), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Disc’s pipe
Even if it's not a huge purchase, we think it was good to see that Braden Leonard, a Gemini Therapeutics, Inc...
Remote-First-Company/Mass., March 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021.
GMTX Price Returns